CryoPort (CYRX) Competitors $7.55 +0.04 (+0.53%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$7.55 0.00 (0.00%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYRX vs. JANX, BHVN, ANIP, MESO, EWTX, TVTX, CVAC, PAHC, ABCL, and CALTShould you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Janux Therapeutics (JANX), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. CryoPort vs. Its Competitors Janux Therapeutics Biohaven ANI Pharmaceuticals Mesoblast Edgewise Therapeutics Travere Therapeutics CureVac Phibro Animal Health AbCellera Biologics Calliditas Therapeutics AB (publ) Janux Therapeutics (NASDAQ:JANX) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Is JANX or CYRX more profitable? Janux Therapeutics has a net margin of 0.00% compared to CryoPort's net margin of -50.15%. Janux Therapeutics' return on equity of -9.29% beat CryoPort's return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -9.29% -8.89% CryoPort -50.15%-11.03%-5.54% Do analysts prefer JANX or CYRX? Janux Therapeutics currently has a consensus target price of $91.89, indicating a potential upside of 265.36%. CryoPort has a consensus target price of $10.88, indicating a potential upside of 44.04%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Janux Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08CryoPort 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders and institutionals believe in JANX or CYRX? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by insiders. Comparatively, 10.0% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor JANX or CYRX? In the previous week, CryoPort had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for CryoPort and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.72 beat CryoPort's score of 0.04 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, JANX or CYRX? Janux Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Which has preferable valuation and earnings, JANX or CYRX? Janux Therapeutics has higher earnings, but lower revenue than CryoPort. Janux Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M140.52-$68.99M-$1.36-18.49CryoPort$228.38M1.66-$114.76M-$2.34-3.23 SummaryJanux Therapeutics beats CryoPort on 11 of the 17 factors compared between the two stocks. Get CryoPort News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoPortTRANS IndustryTransportation SectorNASDAQ ExchangeMarket Cap$378.53M$5.95B$7.28B$9.11BDividend YieldN/A2.28%922.81%4.01%P/E Ratio-3.2310.6713.2320.26Price / Sales1.661.21357.44101.33Price / CashN/A10.937.6257.67Price / Book1.013.012.145.49Net Income-$114.76M$189.74M$563.51M$250.45M7 Day Performance-1.18%-0.55%2.13%4.78%1 Month Performance13.19%2.97%5.33%9.58%1 Year Performance5.30%-3.93%4.98%16.41% CryoPort Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoPort1.6457 of 5 stars$7.55+0.5%$10.88+44.0%+5.3%$378.53M$228.38M-3.231,186JANXJanux Therapeutics1.9095 of 5 stars$23.96-2.0%$95.25+297.5%-43.1%$1.42B$10.59M-17.6230News CoverageAnalyst ForecastBHVNBiohaven3.1568 of 5 stars$13.81-5.6%$58.46+323.3%-63.5%$1.41BN/A-1.48239Gap DownANIPANI Pharmaceuticals3.6377 of 5 stars$64.91-0.6%$80.13+23.4%+2.3%$1.41B$614.38M-51.11600News CoverageAnalyst ForecastAnalyst RevisionMESOMesoblast2.3375 of 5 stars$10.53-1.4%$18.00+70.9%+38.0%$1.35B$5.90M0.0080Positive NewsEWTXEdgewise Therapeutics1.4876 of 5 stars$12.61-3.2%$40.00+217.2%-38.3%$1.33BN/A-8.1460TVTXTravere Therapeutics3.7051 of 5 stars$14.60-2.7%$32.14+120.2%+68.1%$1.30B$273.53M-5.20460Positive NewsCVACCureVac4.6882 of 5 stars$5.41-0.7%$6.83+26.3%+67.5%$1.21B$523.70M5.88880Positive NewsPAHCPhibro Animal Health4.0475 of 5 stars$29.90+6.8%$24.40-18.4%+76.2%$1.21B$1.02B38.331,940High Trading VolumeABCLAbCellera Biologics2.129 of 5 stars$4.03+6.1%$7.50+86.1%+28.5%$1.20B$28.83M-7.20500News CoverageAnalyst RevisionHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Janux Therapeutics Competitors Biohaven Competitors ANI Pharmaceuticals Competitors Mesoblast Competitors Edgewise Therapeutics Competitors Travere Therapeutics Competitors CureVac Competitors Phibro Animal Health Competitors AbCellera Biologics Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYRX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoPort, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CryoPort With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYRX Stock Alerts